FDA has removed 12 of 19 restricted peptides from Category 2, and the PCAC convenes July 23–24 to evaluate their inclusion on the 503A Bulks List. This congress meets in the critical window following those hearings — to ensure the science is heard, the process moves forward, and expanded access becomes a reality.
20+ sessions bridging bench research to bedside practice from leading peptide clinicians and researchers.
Congress is in session. FDA, NIH, and HHS are next door. Shape the future of peptide regulation where decisions are made.
Hands-on workshops for physicians and pharmacists. Real protocols, real cases, real clinical outcomes.
300 physicians, pharmacists, manufacturers, researchers, and legislators — the entire peptide ecosystem, one roof.
Corcoran Ballroom
2800 Pennsylvania Ave NW, Washington, DC 20007
Five-star hotel in Georgetown, at the edge of Rock Creek Park and steps from the Georgetown waterfront — a short distance from the Kennedy Center and the National Mall.
